| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study
|
Scheinberg, Phillip
|
|
|
11 |
3 |
p. e206-e215
|
article
|
| 2 |
A thank you to our 2023 reviewers and update on inclusion and diversity commitments
|
The Editors of The Lancet Haematology,
|
|
|
11 |
3 |
p. e176-e177
|
article
|
| 3 |
Balancing the risks and benefits of CAR T-cell therapy
|
The Lancet Haematology,
|
|
|
11 |
3 |
p. e169
|
article
|
| 4 |
Celebrating our community: a call for essays and art
|
The Editors of The Lancet Haematology,
|
|
|
11 |
3 |
p. e177
|
article
|
| 5 |
Clinical implications and insights from patient-reported outcome data in KarMMa-3
|
Chakraborty, Rajshekhar
|
|
|
11 |
3 |
p. e175-e176
|
article
|
| 6 |
Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia
|
Groarke, Emma M
|
|
|
11 |
3 |
p. e173-e174
|
article
|
| 7 |
Correction to Lancet Haematol 2024; 11: e101–13
|
|
|
|
11 |
3 |
p. e181
|
article
|
| 8 |
Correction to Lancet Haematol 2023; 10: e203–12
|
|
|
|
11 |
3 |
p. e181
|
article
|
| 9 |
Correction to Lancet Haematol 2024; 11: e38–50
|
|
|
|
11 |
3 |
p. e181
|
article
|
| 10 |
Correction to Lancet Haematol 2024; 11: e168
|
|
|
|
11 |
3 |
p. e181
|
article
|
| 11 |
Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia
|
Assouline, Sarit
|
|
|
11 |
3 |
p. e170-e171
|
article
|
| 12 |
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
|
Al-Samkari, Hanny
|
|
|
11 |
3 |
p. e228-e239
|
article
|
| 13 |
Extending potentially curative options for older patients with PCNSL
|
Phillips, Elizabeth H
|
|
|
11 |
3 |
p. e171-e173
|
article
|
| 14 |
Gender composition and geographical representation of American Society of Hematology clinical practice guideline authors
|
Jacobs, Jeremy W
|
|
|
11 |
3 |
p. e182-e183
|
article
|
| 15 |
Health-care transition services for sickle cell disease in Brazil
|
Hankins, Jane S
|
|
|
11 |
3 |
p. e184-e185
|
article
|
| 16 |
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
|
Delforge, Michel
|
|
|
11 |
3 |
p. e216-e227
|
article
|
| 17 |
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
|
Schorb, Elisabeth
|
|
|
11 |
3 |
p. e196-e205
|
article
|
| 18 |
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
|
Bataller, Alex
|
|
|
11 |
3 |
p. e186-e195
|
article
|
| 19 |
Thank you to The Lancet Haematology's peer reviewers in 2023
|
The Lancet Haematology Editors,
|
|
|
11 |
3 |
p. e178-e180
|
article
|
| 20 |
Thrombotic complications of immune thrombocytopenic purpura
|
Qian, Philip
|
|
|
11 |
3 |
p. e240
|
article
|
Journal description